Pretreatment with Glucocorticoids Enhances T-Cell Effector Function: Possible Implication for Immune Rebound Accompanying Glucocorticoid Withdrawal
Open Access
- 1 November 1999
- journal article
- research article
- Published by SAGE Publications in Cell Transplantation
- Vol. 8 (6) , 637-647
- https://doi.org/10.1177/096368979900800610
Abstract
Glucocorticoids (GCs) exert their immunosuppressive/antiproliferative effects largely through inhibition of cytokine expression, and paradoxically upregulate the expression of (proinflammatory) cytokine receptors on select nonlymphoid cells. Clinically, withdrawal of GCs was frequently associated with worsening of the outcome of heightened immunity disorders, thereby implicating enhanced cytokine and cytokine receptor expression as a possible consequence of acute/short-term GCs withdrawal. In view of the significance of this complication of GC therapy, we addressed the effect of GC withdrawal on cytokine receptor expression and subsequent T-cell effector function, using the proliferation of human T cells as biological readout. To mimic GC withdrawal, T cells were treated with GCs or controls, stimulated, and incubated for 16–20 h at 37°C, washed, and reactivated for a further 4–48 h. Surface marker expression was assessed by FACS analysis, and proliferation was determined by measuring the cellular uptake of tritiated thymidine. Dexamethasone (DEX) and prednisolone (PRED), in a concentration-dependent manner, inhibited T-cell proliferation induced by anti-CD28 Ab + PMA. However, pretreatment of T cells activated with mitogens, cross-linking antibodies, or PMA + ionomycin (“CD3-bypass” stimulation regimen), but not resting T cells, with DEX or PRED resulted in a marked increase in IL-1R, IL-2Rα, and IL-6R expression, which was accompanied by a significant enhancement in T-cell proliferation. This effect of GCs was neither stimulus specific nor did it result from alteration in cell viability, and was paralleled by augmentation in cytokine (rIL-2) effects on DEX-pretreated and preactivated T cells. Taken together, our results underline the dual effects of GCs in regulating T-cell activation and cytokine expression. In essence, GCs directly inhibited T-cell proliferation by suppressing cytokine production, and, by enhancing cytokine receptor expression, pretreatment with GCs augmented T-cell proliferation.Keywords
This publication has 27 references indexed in Scilit:
- TRENDS IN THE USE OF GLUCOCORTICOIDS IN RENAL TRANSPLANTATIONTransplantation, 1994
- Differential effect of glucocorticoids on tumour necrosis factor production in mice: up-regulation by early pretreatment with dexamethasoneClinical and Experimental Immunology, 1994
- Glucocorticoid Hormones Upregulate Interleukin 2 Receptor α Gene ExpressionCellular Immunology, 1993
- Immunosuppression by Glucocorticoids: Inhibition of Production of Multiple Lymphokines by in Vivo Administration of DexamethasoneCellular Immunology, 1993
- Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT.Journal of Clinical Investigation, 1993
- WITHDRAWAL OF STEROIDS AFTER RENAL TRANSPLANTATION—CLINICAL PREDICTORS OF OUTCOME1Transplantation, 1992
- Role of the CD28 receptor in T-cell activationImmunology Today, 1990
- Gene regulation by steroid hormonesCell, 1989
- Inhibition of interleukin 2-induced proliferation of cloned murine T cells by glucocorticoids. Possible involvement of an inhibitory proteinEuropean Journal of Immunology, 1988
- WITHDRAWAL OF STEROID IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTSTransplantation, 1988